Synthon's ambition is to become a recognized leader in specialty pharmaceuticals, focusing on autoimmune/neurodegenerative diseases - particularly multiple sclerosis (MS) - and oncology.
Synthon’s strategy from its inception included development of a vertically integrated organization for small molecule generics, controlling every facet of the development chain beginning with the production of raw materials through to manufacture and sale of our products.
We further extended this model to our newer technological platforms of biosimilars and new biological and new chemical entities. The combination of innovative R&D and proven ability to manufacture and distribute high quality pharmaceuticals positions us well for our future in specialty pharmaceuticals.
Our products are currently approved by regulatory agencies in over 80 countries worldwide and are marketed through strategic partnerships and – in dedicated areas – through direct sales. Our worldwide supply chain and manufacturing infrastructure meets the highest standards of quality and performance.
We believe in a collaborative model, based upon strong partnerships with leading scientists, research institutions and partner companies.
Our strategy of developing robust business-to-business partnerships enables us to share knowledge with and draw upon the specialist skills of partner companies. This helps to manage costs, deliver short product development cycle times and bring much-needed products to market.
Such has been the success of our efforts that since 2005, the number of partner companies increased from around 60 to over 200 today.